The expression of ADAM10 and UBE2T in ovarian cancer tissue and their relationship with clinical pathological fea-tures and prognosis of patients

Wang Jie; Fan Lei; Liu Jing; He Zhuo; Zhu Pengfei

doi:10.3969/j.issn.1671-6450.2025.06.010

Abstract：Objective To investigate the expression of a disintegrin and metalloprotease 10(ADAM10),ubiquitin-conjugating enzyme E2T(UBE2T)in ovarian cancer tissues and their relationship with clinical pathological features and prog-nosis of patients.Methods From September,2020 to September,2023,78 cases of ovarian cancer were diagnosed by pa-thology after gynecological treatment in Tongchuan People's Hospital(North Hospital),Shaanxi Province.The relationship be-tween the expression of ADAM1 0 and UBE2T in ovarian cancer tissues and prognosis was analyzed using Kaplan-Meier method.The factors influencing the prognosis of ovarian cancer patients were analyzed using multiple Logistic regression.Re-sults The positive expression rates of ADAM 10 and UBE2T in ovarian cancer tissues were greatly higher than those in adja-cent tissues(x2=12.955,13.952,P＜0.001).The expressions of ADAM10 and UBE2T in ovarian cancer were higher than those in FIGO Ⅲ～Ⅳ,lymph node metastasis and low differentiation,and no lymph node metastasis and moderate/high differ-entiation(x2/P=14.857/＜0.001,9.916/0.002,10.858/0.001,13.791/＜0.001,16.458/＜0.001,6.334/0.012).The 78 ovarian cancer patients were followed up for 1 year,with a total of 56 survivors and 22 deaths.The overall 1-year survival rate was 71.79％(56/78).The positive expression rate of ADAM10 and UBE2T in ovarian cancer tissue of death subgroup was higher than that of survival subgroup(x2=13.038,14.832,P＜0.001).There was a statistically significant difference in the proportions of patients in subgroup 2 with FIGO stageⅢ-Ⅳ,lymph node metastasis,and low degree of differentiation(x2/P=8.104/0.004,7.503/0.006,9.254/0.002).The one-year survival rates of patients with positive expression of ADAM10 and UBE2T in ovarian cancer tissues were 54.76％(23/42)and 54.55％(24/44),respectively.The one-year survival rates of patients with negative expression of ADAM10 and UBE2T were 91.67％(33/36)and 94.12％(32/34),respectively.The one-year survival rates of patients with positive expression of ADAM 10 and UBE2T in ovarian cancer tissues were greatly lower than those of patients with negative expression of ADAM10 and UBE2T(Log Rank x2=13.305,13.978,P＜0.01).FIGO Ⅲ～Ⅳ stage,lymph node metastasis,low degree of differentiation,positive ADAM10 and UBE2T were independent risk factors for the prognosis of ovarian cancer patients[OR(95％CI)=2.537(1.545-1.166),2.614(1.646-4.151),1.3 97(1.297-3.001),2.625(1.481-4.625),1.674(1.245-2.251)].Conclusion The positive expression of ADAM10 and UBE2T in ovarian cancer tissues is closely relat-ed to the clinical pathological features and prognosis of patients.